Epigenetic Regulation of Tumor Immunity

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2024 Aug 12

PMID 39133578

Authors

Lizhi Pang

Fei Zhou

Yang Liu

Heba Ali

Fatima Khan

Amy B Heimberger

Peiwen Chen

Affiliations

Soon will be listed here.

Abstract

Although cancer has long been considered a genetic disease, increasing evidence shows that epigenetic aberrations play a crucial role in affecting tumor biology and therapeutic response. The dysregulated epigenome in cancer cells reprograms the immune landscape within the tumor microenvironment, thereby hindering antitumor immunity, promoting tumor progression, and inducing immunotherapy resistance. Targeting epigenetically mediated tumor-immune crosstalk is an emerging strategy to inhibit tumor progression and circumvent the limitations of current immunotherapies, including immune checkpoint inhibitors. In this Review, we discuss the mechanisms by which epigenetic aberrations regulate tumor-immune interactions and how epigenetically targeted therapies inhibit tumor progression and synergize with immunotherapy.

Citing Articles

Exploring viral mimicry combined with epigenetics and tumor immunity: new perspectives in cancer therapy.

Wang R, Dong X, Zhang X, Liao J, Cui W, Li W Int J Biol Sci. 2025; 21(3):958-973.

PMID: 39897033 PMC: 11781167. DOI: 10.7150/ijbs.103877.

Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9.

Fan T, Xiao C, Deng Z, Li S, Tian H, Zheng Y Respir Res. 2025; 26(1):17.

PMID: 39815269 PMC: 11734478. DOI: 10.1186/s12931-024-03093-6.

Epigenetics-targeted drugs: current paradigms and future challenges.

Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.

PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.

Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma.

Liu Y, Wu J, Najem H, Lin Y, Pang L, Khan F J Clin Invest. 2024; 134(22).

PMID: 39352749 PMC: 11563674. DOI: 10.1172/JCI178628.

Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?.

Hossain S, Ly K, Sung Y, Braithwaite A, Li K Int J Mol Sci. 2024; 25(18).

PMID: 39337605 PMC: 11432671. DOI: 10.3390/ijms251810120.

References

Souroullas G, Jeck W, Parker J, Simon J, Liu J, Paulk J . An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat Med. 2016; 22(6):632-40. PMC: 4899144. DOI: 10.1038/nm.4092. View

Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K . MA Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma. Cancer Res. 2021; 81(18):4778-4793. DOI: 10.1158/0008-5472.CAN-21-0468. View

Lu Z, Zou J, Li S, Topper M, Tao Y, Zhang H . Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020; 579(7798):284-290. PMC: 8765085. DOI: 10.1038/s41586-020-2054-x. View

Topper M, Vaz M, Marrone K, Brahmer J, Baylin S . The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2019; 17(2):75-90. PMC: 7254932. DOI: 10.1038/s41571-019-0266-5. View

Porta C, Consonni F, Morlacchi S, Sangaletti S, Bleve A, Totaro M . Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. Cancer Res. 2020; 80(13):2874-2888. DOI: 10.1158/0008-5472.CAN-19-2843. View

Chen Z, Yang X, Chen Z, Li M, Wang W, Yang R . A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy. BMC Med. 2023; 21(1):402. PMC: 10601128. DOI: 10.1186/s12916-023-03094-0. View

Ni H, Zhang L, Huang H, Dai S, Li J . Connecting METTL3 and intratumoural CD33 MDSCs in predicting clinical outcome in cervical cancer. J Transl Med. 2020; 18(1):393. PMC: 7565373. DOI: 10.1186/s12967-020-02553-z. View

Dong L, Chen C, Zhang Y, Guo P, Wang Z, Li J . The loss of RNA N-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8 T cell dysfunction and tumor growth. Cancer Cell. 2021; 39(7):945-957.e10. DOI: 10.1016/j.ccell.2021.04.016. View

Soriano-Baguet L, Brenner D . Metabolism and epigenetics at the heart of T cell function. Trends Immunol. 2023; 44(3):231-244. DOI: 10.1016/j.it.2023.01.002. View

10.

Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E . An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019; 36(4):385-401.e8. PMC: 6876280. DOI: 10.1016/j.ccell.2019.08.008. View

11.

Foskolou I, Cunha P, Sanchez-Lopez E, Minogue E, Nicolet B, Guislain A . The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function. Cell Rep. 2023; 42(9):113013. DOI: 10.1016/j.celrep.2023.113013. View

12.

Fu Y, Zhang X, Liu X, Wang P, Chu W, Zhao W . The DNMT1-PAS1-PH20 axis drives breast cancer growth and metastasis. Signal Transduct Target Ther. 2022; 7(1):81. PMC: 8934873. DOI: 10.1038/s41392-022-00896-1. View

13.

Chen P, Hsu W, Han J, Xia Y, DePinho R . Cancer Stemness Meets Immunity: From Mechanism to Therapy. Cell Rep. 2021; 34(1):108597. PMC: 7839836. DOI: 10.1016/j.celrep.2020.108597. View

14.

Shang W, Gao Y, Tang Z, Zhang Y, Yang R . The Pseudogene Promotes the Suppressive Function and Differentiation of Monocytic MDSCs. Cancer Immunol Res. 2019; 7(5):813-827. DOI: 10.1158/2326-6066.CIR-18-0443. View

15.

Amankulor N, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M . Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017; 31(8):774-786. PMC: 5435890. DOI: 10.1101/gad.294991.116. View

16.

Pappalardi M, Keenan K, Cockerill M, Kellner W, Stowell A, Sherk C . Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021; 2(10):1002-1017. PMC: 8594913. View

17.

Zhang M, Liu Z, Aoshima K, Cai W, Sun H, Xu T . CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. Sci Transl Med. 2022; 14(630):eabf5473. PMC: 9003667. DOI: 10.1126/scitranslmed.abf5473. View

18.

Itahashi K, Irie T, Yuda J, Kumagai S, Tanegashima T, Lin Y . BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci Immunol. 2022; 7(76):eabk0957. DOI: 10.1126/sciimmunol.abk0957. View

19.

Li Y, Goldberg E, Chen X, Xu X, McGuire J, Leuzzi G . Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Mol Cell. 2022; 82(20):3901-3918.e7. PMC: 9588679. DOI: 10.1016/j.molcel.2022.09.007. View

20.

Li J, Lan Z, Liao W, Horner J, Xu X, Liu J . Histone demethylase KDM5D upregulation drives sex differences in colon cancer. Nature. 2023; 619(7970):632-639. PMC: 10529424. DOI: 10.1038/s41586-023-06254-7. View